Pluvicto Moves Earlier in PSMA-Positive Prostate Cancer

Who becomes eligible

The FDA’s July 31, 2026 decision expands lutetium Lu-177 vipivotide tetraxetan (Pluvicto) into PSMA-positive metastatic prostate cancer that remains sensitive to androgen pathway modulation. Treatment is given with an androgen receptor pathway inhibitor, or ARPI, rather than as a replacement for systemic hormonal therapy.

This is a distinct population from metastatic castration-resistant prostate cancer, where the radioligand was first established. Castration-resistant disease progresses despite suppression of testosterone. Hormone-sensitive, or castration-sensitive, disease still responds to androgen pathway treatment, even when metastases are already present and androgen-deprivation therapy has begun.

The newly eligible group can therefore include people presenting with metastatic disease and those whose cancer recurs at distant sites after prior local treatment, provided the disease remains hormone-sensitive and meets the label’s PSMA-imaging criteria. “Androgen pathway modulation-naïve or -sensitive” should not be read as synonymous with completely untreated. Prior surgery, radiotherapy, androgen deprivation or other therapy may be compatible with eligibility, but the permitted timing and duration of previous systemic treatment must be checked against the final prescribing information.

PSMA positivity is also more than a pathology description. Selection for lutetium Lu-177 vipivotide tetraxetan depends on PSMA-targeted imaging and the criteria specified in the approved label. A patient with metastatic hormone-sensitive disease is not automatically a candidate if uptake is absent, heterogeneous or otherwise outside those criteria.

What supports the move into hormone-sensitive disease

The relevant phase 3 development program evaluated lutetium Lu-177 vipivotide tetraxetan added to standard treatment in PSMA-positive metastatic hormone-sensitive prostate cancer. The ClinicalTrials.gov record describes PSMAddition as a randomized, open-label study comparing the radioligand plus standard-of-care hormonal treatment with standard care alone. Radiographic progression-free survival is a principal efficacy outcome, with overall survival and other clinical outcomes included in the assessment.

The regulatory decision establishes that the FDA judged the benefit-risk balance favorable for the labeled population. It should not, however, be converted into a numerical efficacy claim without the decision-specific review, label or primary trial report. The approval-notification index supplied for this brief does not itself provide the analyzed population, effect estimate, confidence interval or median follow-up. Those figures are necessary before stating how much the combination delayed progression or whether it improved overall survival.

That distinction matters because progression-free and overall survival answer different questions. A radiographic progression-free survival advantage may support earlier disease control, but it does not by itself establish longer life, better quality of life or superiority over every other accepted intensification strategy. Overall survival can also be difficult to interpret when subsequent therapies and treatment crossover differ between groups.

Earlier evidence came from a later clinical state. In the randomized phase 3 VISION trial, lutetium-177–PSMA-617 improved radiographic progression-free and overall survival when added to protocol-permitted standard care for previously treated PSMA-positive metastatic castration-resistant prostate cancer. Those findings established the therapeutic principle of delivering beta radiation to PSMA-expressing tumors, but they cannot quantify benefit in hormone-sensitive disease, where prognosis, competing treatments and prior exposure differ.

How sequencing may change

The practical change is not simply another line on a treatment list. Radioligand therapy can now enter the treatment plan while disease remains responsive to androgen pathway suppression. That may shift multidisciplinary discussions toward PSMA PET imaging and nuclear medicine consultation earlier in the metastatic course.

Until this expansion, clinicians could generally preserve lutetium Lu-177 vipivotide tetraxetan for castration-resistant disease, after substantial exposure to hormonal therapy and, in the original VISION population, taxane chemotherapy. Earlier eligibility creates a choice between using radioligand therapy during the first hormone-sensitive phase and reserving it for later progression. The approval confirms that early use is an available strategy; it does not prove that every eligible patient benefits more from receiving it immediately than from preserving it for a later line.

Treatment selection remains shaped by disease volume and distribution, symptoms, pace of progression, comorbidities, previous treatment, access and patient priorities. Docetaxel and combinations built around androgen deprivation and an ARPI remain relevant comparators in US practice, particularly because the pivotal radioligand study did not necessarily test every contemporary sequence head to head.

Capacity is a policy issue as well as a clinical one. Earlier use enlarges the potential treatment population and may increase demand for PSMA PET imaging, radiopharmaceutical production, authorized treatment sites, radiation-safety infrastructure and coordination among medical oncology, urology, nuclear medicine and radiation oncology. Coverage policies will need to track the final FDA indication rather than older criteria limited to castration-resistant disease.

Safety also carries different implications when treatment begins earlier. Bone-marrow suppression, renal considerations, radiation precautions and treatment burden must be weighed over a potentially longer remaining lifespan. Earlier exposure may affect whether retreatment or another radiopharmaceutical can be used later, but a regulatory approval alone does not resolve that sequencing question.

Important gaps after approval

The central limitation of this briefing is source granularity. The supplied FDA page is an oncology approval index, not a decision-specific multidisciplinary review or complete prescribing label. It confirms the regulatory action described in the evidence brief but does not expose the pivotal analysis numbers needed for a precise account of effect size, confidence intervals, follow-up and adverse-event frequency.

The pivotal study’s open-label design can influence treatment discontinuation, reporting of symptoms and subsequent care, although blinded central assessment can reduce bias in imaging-based outcomes when used. Generalizability also depends on who was enrolled: trial participants selected by PSMA imaging, organ function and performance status may not represent patients with frailty, extensive marrow involvement, impaired renal function or heterogeneous PSMA expression.

Longer follow-up is needed to define mature overall survival, late marrow effects, second malignancies, quality of life and the consequences of using a finite radioligand option earlier. Evidence is also needed on the best approach after progression: whether patients can be treated again, how well taxanes work afterward, and whether early radioligand therapy changes sensitivity to later androgen-axis treatments.

Questions clinicians ask

Does every patient with metastatic hormone-sensitive disease now need PSMA PET imaging?

The approval makes PSMA status essential when lutetium Lu-177 vipivotide tetraxetan is being considered. It does not by itself establish that every patient must undergo PSMA PET irrespective of treatment intent; imaging should be tied to the label, local staging practice and whether the result would alter management.

Can the radioligand replace androgen deprivation or an ARPI?

No. The decision covers lutetium Lu-177 vipivotide tetraxetan in combination with an ARPI, not radioligand monotherapy as a substitute for androgen pathway treatment. The final label should be consulted for required background therapy and the boundaries of permitted previous treatment.

Should eligible patients receive Pluvicto before docetaxel?

The approval creates that possibility but does not establish a universal sequence. Choice should reflect the pivotal trial population, the exact label, disease characteristics, comorbidities and patient preferences; cross-trial comparisons cannot determine whether early radioligand therapy is superior to every docetaxel-containing strategy.

What information is still needed before applying the decision broadly?

Clinicians need the decision-specific effect size, confidence interval, follow-up, adverse-event profile and subgroup results, along with the final imaging and prior-treatment criteria. Mature survival and quality-of-life findings will be especially important for judging the trade-off between earlier disease control and preserving radioligand therapy for later disease.

References

1. Oncology (Cancer)/Hematologic Malignancies Approval Notifications — US Food and Drug Administration, 2026 2. A Study of 177Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer (PSMAddition) — ClinicalTrials.gov, 2021 3. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer — The New England Journal of Medicine, 2021 4. Prostate Cancer Treatment (PDQ)–Health Professional Version — National Cancer Institute, 2024